XENOGEN CORPORATION INDEMNIFICATION AGREEMENTIndemnification Agreement • June 15th, 2004 • Xenogen Corp • Services-commercial physical & biological research • Delaware
This Indemnification Agreement (“Agreement”) is effective as of , by and between Xenogen Corporation, a Delaware corporation (the “Company”), and the indemnitee listed on the signature page hereto (“Indemnitee”).
CONFIDENTIAL TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION.]Commercial License Agreement • June 15th, 2004 • Xenogen Corp • Services-commercial physical & biological research • California
This Agreement (the “Agreement”) effective as of July 12, 2000 (the “Effective Date”) is made by and between Xenogen Corporation, having a principal place of business at 860 Atlantic Avenue, Alameda, California 94501 (“Xenogen”) and IRM, LLC, a Delaware Corporation, (“IRM”), having a principal place of business at Sofia House, 48 Church Street, Hamilton, Bermuda.
ContractXenogen Corp • June 15th, 2004 • Services-commercial physical & biological research
[Confidential Treatment Requested. Portions of this agreement have been redacted and filed separately with the commission.]
DISTRIBUTOR AGREEMENT between Xenogen Corporation 860 Atlantic Avenue Alameda, CA 94501 and SC BioSciences Corporation Izumi Shiba-Daimon Bldg. 3F 2-2-11, Shiba-Daimon Minato-ku, Tokyo, 105-0012 JapanLicense End User Agreement • June 15th, 2004 • Xenogen Corp • Services-commercial physical & biological research • California
extent it contains subject matter deriving a priority date from the original patent application) extensions, renewals, reissues and reexaminations of the foregoing patents (including patents issuing on the foregoing patent applications or resulting from reissues or re-examinations) in the Territory.
MARKETING SERVICES AGREEMENTMarketing Services Agreement • June 15th, 2004 • Xenogen Corp • Services-commercial physical & biological research • Massachusetts
This Marketing Services Agreement (the “Agreement”) is entered into as of Apr 2, 2003 (the “Effective Date”) by and between Charles River Laboratories, Inc., a Delaware corporation with its principal place of business at 251 Ballardvale Street, Wilmington, Massachusetts 01887 (“Charles River”), Xenogen Corporation, a Delaware corporation with its principal place of business a 860 Atlantic Avenue, Alameda, California, 94501 (“Xenogen”) and Xenogen Biosciences Corporation, an Ohio corporation with its principal place of business at 5 Cedar Brook Drive, Cranbury, NJ 08512 (“XenogenBio”).
CONFIDENTIAL TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN REDACTED AND SEPARATELY FILED WITH THE COMMISSION.] COLLABORATIVE RESEARCH AGREEMENTCollaborative Research Agreement • June 15th, 2004 • Xenogen Corp • Services-commercial physical & biological research • New Jersey
This COLLABORATIVE RESEARCH AGREEMENT (“Agreement”) is entered into as of December 28, 2000 by and between PFIZER INC, a Delaware corporation, having an office at 235 East 42nd Street, New York, New York 10017 and its Affiliates (“Pfizer”), and XENOGEN BIOSCIENCES (“Xenogen Cranbury”), an Ohio Corporation, with an office at 5 Cedar Brook Drive, Cranbury, NJ 08512, and a wholly owned subsidiary of Xenogen Corp. (“Xenogen”).
COLLABORATIVE RESEARCH AGREEMENTCollaborative Research Agreement • June 15th, 2004 • Xenogen Corp • Services-commercial physical & biological research • New Jersey
This COLLABORATIVE RESEARCH AGREEMENT (“Agreement”) is entered into as of September 30,2001 by and between PFIZER INC, a Delaware corporation, having an office at 235 East 42nd Street, New York, New York 10017 and its Affiliates (“Pfizer”), and XENOGEN BIOSCIENCES (“Xenogen Cranbury”), an Ohio Corporation, with an office at 5 Cedar Brook Drive, Cranbury, NJ 08512, and a wholly owned subsidiary of Xenogen Corp. (“Xenogen”).
